Literature DB >> 24029233

The RasGAP gene, RASAL2, is a tumor and metastasis suppressor.

Sara Koenig McLaughlin1, Sarah Naomi Olsen, Benjamin Dake, Thomas De Raedt, Elgene Lim, Roderick Terry Bronson, Rameen Beroukhim, Kornelia Polyak, Myles Brown, Charlotte Kuperwasser, Karen Cichowski.   

Abstract

RAS genes are commonly mutated in cancer; however, RAS mutations are rare in breast cancer, despite frequent hyperactivation of Ras and ERK. Here, we report that the RasGAP gene, RASAL2, functions as a tumor and metastasis suppressor. RASAL2 is mutated or suppressed in human breast cancer, and RASAL2 ablation promotes tumor growth, progression, and metastasis in mouse models. In human breast cancer, RASAL2 loss is associated with metastatic disease; low RASAL2 levels correlate with recurrence of luminal B tumors; and RASAL2 ablation promotes metastasis of luminal mouse tumors. Additional data reveal a broader role for RASAL2 inactivation in other tumor types. These studies highlight the expanding role of RasGAPs and reveal an alternative mechanism of activating Ras in cancer.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24029233      PMCID: PMC3822334          DOI: 10.1016/j.ccr.2013.08.004

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  48 in total

1.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.

Authors:  Balazs Györffy; Andras Lanczky; Aron C Eklund; Carsten Denkert; Jan Budczies; Qiyuan Li; Zoltan Szallasi
Journal:  Breast Cancer Res Treat       Date:  2009-12-18       Impact factor: 4.872

Review 2.  Mouse models for breast cancer metastasis.

Authors:  Ik Soo Kim; Sung Hee Baek
Journal:  Biochem Biophys Res Commun       Date:  2010-03-15       Impact factor: 3.575

3.  NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome.

Authors:  Michael Hölzel; Sidong Huang; Jan Koster; Ingrid Ora; Arjan Lakeman; Huib Caron; Wouter Nijkamp; Jing Xie; Tom Callens; Shahab Asgharzadeh; Robert C Seeger; Ludwine Messiaen; Rogier Versteeg; René Bernards
Journal:  Cell       Date:  2010-07-23       Impact factor: 41.582

4.  An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.

Authors:  Junxia Min; Alexander Zaslavsky; Giuseppe Fedele; Sara K McLaughlin; Elizabeth E Reczek; Thomas De Raedt; Isil Guney; David E Strochlic; Laura E Macconaill; Rameen Beroukhim; Roderick T Bronson; Sandra Ryeom; William C Hahn; Massimo Loda; Karen Cichowski
Journal:  Nat Med       Date:  2010-02-14       Impact factor: 53.440

5.  A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.

Authors:  Andrey Loboda; Michael Nebozhyn; Rich Klinghoffer; Jason Frazier; Michael Chastain; William Arthur; Brian Roberts; Theresa Zhang; Melissa Chenard; Brian Haines; Jannik Andersen; Kumiko Nagashima; Cloud Paweletz; Bethany Lynch; Igor Feldman; Hongyue Dai; Pearl Huang; James Watters
Journal:  BMC Med Genomics       Date:  2010-06-30       Impact factor: 3.063

6.  Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.

Authors:  Lauren T McGillicuddy; Jody A Fromm; Pablo E Hollstein; Sara Kubek; Rameen Beroukhim; Thomas De Raedt; Bryan W Johnson; Sybil M G Williams; Phioanh Nghiemphu; Linda M Liau; Tim F Cloughesy; Paul S Mischel; Annabel Parret; Jeanette Seiler; Gerd Moldenhauer; Klaus Scheffzek; Anat O Stemmer-Rachamimov; Charles L Sawyers; Cameron Brennan; Ludwine Messiaen; Ingo K Mellinghoff; Karen Cichowski
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

7.  Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.

Authors:  Christina Gewinner; Zhigang C Wang; Andrea Richardson; Julie Teruya-Feldstein; Dariush Etemadmoghadam; David Bowtell; Jordi Barretina; William M Lin; Lucia Rameh; Leonardo Salmena; Pier Paolo Pandolfi; Lewis C Cantley
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

8.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.

Authors:  Elgene Lim; François Vaillant; Di Wu; Natasha C Forrest; Bhupinder Pal; Adam H Hart; Marie-Liesse Asselin-Labat; David E Gyorki; Teresa Ward; Audrey Partanen; Frank Feleppa; Lily I Huschtscha; Heather J Thorne; Stephen B Fox; Max Yan; Juliet D French; Melissa A Brown; Gordon K Smyth; Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Med       Date:  2009-08-02       Impact factor: 53.440

9.  Somatic mutations affect key pathways in lung adenocarcinoma.

Authors:  Li Ding; Gad Getz; David A Wheeler; Elaine R Mardis; Michael D McLellan; Kristian Cibulskis; Carrie Sougnez; Heidi Greulich; Donna M Muzny; Margaret B Morgan; Lucinda Fulton; Robert S Fulton; Qunyuan Zhang; Michael C Wendl; Michael S Lawrence; David E Larson; Ken Chen; David J Dooling; Aniko Sabo; Alicia C Hawes; Hua Shen; Shalini N Jhangiani; Lora R Lewis; Otis Hall; Yiming Zhu; Tittu Mathew; Yanru Ren; Jiqiang Yao; Steven E Scherer; Kerstin Clerc; Ginger A Metcalf; Brian Ng; Aleksandar Milosavljevic; Manuel L Gonzalez-Garay; John R Osborne; Rick Meyer; Xiaoqi Shi; Yuzhu Tang; Daniel C Koboldt; Ling Lin; Rachel Abbott; Tracie L Miner; Craig Pohl; Ginger Fewell; Carrie Haipek; Heather Schmidt; Brian H Dunford-Shore; Aldi Kraja; Seth D Crosby; Christopher S Sawyer; Tammi Vickery; Sacha Sander; Jody Robinson; Wendy Winckler; Jennifer Baldwin; Lucian R Chirieac; Amit Dutt; Tim Fennell; Megan Hanna; Bruce E Johnson; Robert C Onofrio; Roman K Thomas; Giovanni Tonon; Barbara A Weir; Xiaojun Zhao; Liuda Ziaugra; Michael C Zody; Thomas Giordano; Mark B Orringer; Jack A Roth; Margaret R Spitz; Ignacio I Wistuba; Bradley Ozenberger; Peter J Good; Andrew C Chang; David G Beer; Mark A Watson; Marc Ladanyi; Stephen Broderick; Akihiko Yoshizawa; William D Travis; William Pao; Michael A Province; George M Weinstock; Harold E Varmus; Stacey B Gabriel; Eric S Lander; Richard A Gibbs; Matthew Meyerson; Richard K Wilson
Journal:  Nature       Date:  2008-10-23       Impact factor: 49.962

10.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

View more
  60 in total

1.  Candidate chromosome 1 disease susceptibility genes for Sjogren's syndrome xerostomia are narrowed by novel NOD.B10 congenic mice.

Authors:  Patricia K A Mongini; Jill M Kramer; Tomo-O Ishikawa; Harvey Herschman; Donna Esposito
Journal:  Clin Immunol       Date:  2014-03-29       Impact factor: 3.969

Review 2.  Signal transduction in cancer.

Authors:  Richard Sever; Joan S Brugge
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

3.  Ras Signaling in Breast Cancer.

Authors:  Aree Moon
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Ras-Specific GTPase-Activating Proteins-Structures, Mechanisms, and Interactions.

Authors:  Klaus Scheffzek; Giridhar Shivalingaiah
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

Review 5.  RAS Proteins and Their Regulators in Human Disease.

Authors:  Dhirendra K Simanshu; Dwight V Nissley; Frank McCormick
Journal:  Cell       Date:  2017-06-29       Impact factor: 41.582

6.  Characterization of recombinant ELMOD (cell engulfment and motility domain) proteins as GTPase-activating proteins (GAPs) for ARF family GTPases.

Authors:  Anna A Ivanova; Michael P East; Slee L Yi; Richard A Kahn
Journal:  J Biol Chem       Date:  2014-03-10       Impact factor: 5.157

Review 7.  New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling.

Authors:  Keesha E Erickson; Oleksii S Rukhlenko; Richard G Posner; William S Hlavacek; Boris N Kholodenko
Journal:  Semin Cancer Biol       Date:  2018-03-05       Impact factor: 15.707

8.  RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.

Authors:  Takuo Hayashi; Patrice Desmeules; Roger S Smith; Alexander Drilon; Romel Somwar; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2017-11-10       Impact factor: 12.531

Review 9.  N-Methyl-N-nitrosourea as a mammary carcinogenic agent.

Authors:  Ana I Faustino-Rocha; Rita Ferreira; Paula A Oliveira; Adelina Gama; Mário Ginja
Journal:  Tumour Biol       Date:  2015-09-19

10.  Circulating Serum miRNAs as Diagnostic Markers for Colorectal Cancer.

Authors:  Abdel-Rahman N Zekri; Amira Salah El-Din Youssef; Mai M Lotfy; Reham Gabr; Ola S Ahmed; Auhood Nassar; Nehal Hussein; Dalia Omran; Eman Medhat; Salam Eid; Marwa Mahmoud Hussein; Maha Yahia Ismail; Faris Q Alenzi; Abeer A Bahnassy
Journal:  PLoS One       Date:  2016-05-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.